Compare · CLOV vs ELV
CLOV vs ELV
Side-by-side comparison of Clover Health Investments Corp. (CLOV) and Elevance Health Inc. (ELV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLOV and ELV operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $90.24B, about 44.7x CLOV ($2.02B).
- Over the past year, CLOV is up 31.3% and ELV is up 7.4% - CLOV leads by 23.9 points.
- CLOV has been more active in the news (4 items in the past 4 weeks vs 3 for ELV).
- ELV has more recent analyst coverage (23 ratings vs 12 for CLOV).
- Company
- Clover Health Investments Corp.
- Elevance Health Inc.
- Price
- $3.92+2.48%
- $418.31+0.63%
- Market cap
- $2.02B
- $90.24B
- 1M return
- +39.43%
- +12.19%
- 1Y return
- +31.27%
- +7.35%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 4
- 3
- Recent ratings
- 12
- 23
Clover Health Investments Corp.
Clover Health Investments, Corp. operates as a Medicare Advantage insurer in the United States. The company through its software platform provides preferred provider organization and health maintenance organization health plans for Medicare-eligible consumers. Clover Health Investments, Corp. was founded in 2014 and is headquartered in Franklin, Tennessee.
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Latest CLOV
- CEO, Counterpart Health Wai Conrad sold $879,500 worth of shares (220,426 units at $3.99) as part of a pre-agreed trading plan (SEC Form 4)
- Director Edwards Carladenise Armbrister sold $229,687 worth of shares (67,160 units at $3.42), decreasing direct ownership by 19% to 285,432 units (SEC Form 4)
- Interim CFO Thornton Joseph Clay covered exercise/tax liability with 16,942 shares, decreasing direct ownership by 1% to 1,217,584 units (SEC Form 4) (withholding obligation)
- Clover Health Investments Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 144 filed by Clover Health Investments Corp.
- CEO of Clover Care Services Priest Brady Patrick sold $345,097 worth of shares (98,039 units at $3.52), decreasing direct ownership by 5% to 2,040,222 units (SEC Form 4)
- Chief Executive Officer Toy Andrew covered exercise/tax liability with 85,704 shares, decreasing direct ownership by 0.86% to 9,923,301 units (SEC Form 4) (withholding obligation)
- SEC Form 10-Q filed by Clover Health Investments Corp.
- Clover Health Investments Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Clover Health Reports First Quarter 2026 Results
Latest ELV
- Elevance Health Expands Access to Digital Tools, Helping Bridge the Healthcare Digital Divide
- CAO & Controller Penczek Ronald W exercised 1,531 shares at a strike of $294.30 and sold $617,192 worth of shares (1,531 units at $403.13) (SEC Form 4)
- Elevance Health upgraded by Deutsche Bank with a new price target
- Director Schulman Amy W was granted 563 shares, increasing direct ownership by 258% to 781 units (SEC Form 4)
- Director Schneider Ryan M. was granted 563 shares, increasing direct ownership by 9% to 7,163 units (SEC Form 4)
- Director Peru Ramiro G was granted 563 shares, increasing direct ownership by 6% to 9,908 units (SEC Form 4)
- Director Neri Antonio F was granted 563 shares, increasing direct ownership by 11% to 5,488 units (SEC Form 4)
- Director Jallal Bahija was granted 563 shares, increasing direct ownership by 12% to 5,351 units (SEC Form 4)
- Director Hay Lewis Iii was granted 563 shares, increasing direct ownership by 5% to 12,070 units (SEC Form 4)
- Director Dixon Robert L Jr was granted 563 shares, increasing direct ownership by 5% to 10,885 units (SEC Form 4)